Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mainwaring

Showing results (441-450 of 465) with videos related to

Pageof 47
Sort By:
The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal of the National Cancer Institute|July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal of Geriatric Oncology|November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trialsEthan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2018
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized TrialDavid Cella, Bernard Escudier, Nizar M Tannir, et al.
British Journal of Cancer|June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaM E Gore, C Szczylik, C Porta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Performance Status Restriction in Phase III Cancer Clinical TrialsJoseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
The Lancet. Oncology|June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Pageof 47

Showing results (441-450 of 465) with videos related to

Sort By:
Pageof 47
The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal of the National Cancer Institute|July 28, 2019
Sex-Based Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, C David Fuller, Shalini Moningi, et al.
Journal of Geriatric Oncology|November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trialsEthan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2018
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized TrialDavid Cella, Bernard Escudier, Nizar M Tannir, et al.
British Journal of Cancer|June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaM E Gore, C Szczylik, C Porta, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Performance Status Restriction in Phase III Cancer Clinical TrialsJoseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
The Lancet. Oncology|June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
Pageof 47